Facial and total body repigmentation with upadacitinib kept rising through Week 76 in Viti-Up, with higher responses when NB-UVB was added.
News|Articles|October 1, 2026
EADV Congress 2026: Day 2 Recap—6 Headlines to Know
Author(s)Tim Smith
Fact checked by: Victoria Johnson
Check out highlights from news published on Day 2 of the EADV Congress 2026, spanning vitiligo, HS, atopic dermatitis, and more.
Advertisement
Advertisement
Day 2 of the
Related to this article
Tilrekimig, a trispecific IL-4/IL-13/TSLP antibody, met its EASI-75 primary endpoint at all doses in a phase 2 atopic dermatitis trial.
The first controlled study of GLP-1 receptor agonists and nail health found nail detachment in 39% of users versus 9% of controls at EADV 2026.
Check out highlights from news published on Day 1 of the EADV Congress 2026, spanning CSU, atopic dermatitis, HS, and more.
Tulisokibart met its HiSCR50 primary endpoint at 16 weeks in the phase 2b MK-7240-012 trial assessing moderate to severe hidradenitis suppurativa.
Intralesional BO-112 met its main endpoint in the phase 2b SPOTLIGHT-204 trial, with 61% of patients with resectable basal cell carcinoma responding.
The international SkinObservatory study found climate-related skin disease disproportionately affecting low-income nations at EADV 2026.
All 3 zumilokibart doses met the EASI-75 primary end point vs placebo at Week 16 in AbbVie's phase 2 APEX Part B atopic dermatitis study.
Advertisement
Advertisement